Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
•
Renal Cell Carcinoma
What perioperative systemic therapy would you use for a patient with oligometastatic clear cell RCC with a bony metastasis at risk for fracture?
Related Questions
What is your approach to surveillance in patients with no evidence of disease after treatment of oligometastatic renal cell carcinoma?
What are your top takeaways in GU Cancers from ESMO 2024?
How do you manage anemia associated with belzutifan therapy?
Is there still a role for mTOR inhibitors in metastatic RCC in the immunotherapy/TKI era?
What is your preferred regimen for a patient with clear cell RCC, progression after an IO+IO regimen, with a chronic non-healing wound?
Do you routinely continue patients on anti-PD(L)-1 beyond 2 years of treatment while on IO/TKI for metastatic ccRCC?
Would you offer adjuvant immunotherapy (pembrolizumab) for chromophobe RCC with R1 resection?
How would you approach a patient with metastatic renal cell carcinoma who developed a STEMI while on TKI (Lenvatinib) and immunotherapy combination?
How often do you monitor for pancreatitis (check lipase/amylase) while on Axitinib?
How do you manage hypoxia induced by belzutifan?
